Healthcare / Medical DevicesTaipei Exchange
$14.00
-0.20 (-1.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $236.7M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
6.1x
↓ROE
-2.1%
↓Gross Margin
34.4%
↓Debt/Equity
0.95
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.4%
FCF CAGR
-7.5%
FCF margin
6.2%
FCF / Net income
-7.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.80B · net income $-29.9M · FCF $236.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.80B | $3.80B | $3.85B | $3.81B | $4.34B |
| Net Income | $-29.9M | $-29.9M | $-29.3M | $-6.7M | $170.3M |
| EBITDA | $307.8M | $307.8M | $307.9M | $347.1M | $580.0M |
| EPS | — | — | -0.34 | -0.08 | 2.00 |
| Gross Margin | 34.4% | 34.4% | 34.7% | 33.4% | 34.7% |
| Operating Margin | -1.9% | -1.9% | -2.0% | 0.1% | 6.0% |
| Net Margin | -0.8% | -0.8% | -0.8% | -0.2% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.95 | 0.95 | 0.87 | 0.96 | 0.72 |
| Current Ratio | 1.97 | 1.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $236.7M | $236.7M | $238.5M | $195.0M | $299.5M |
| Returns | |||||
| ROE | -2.1% | -2.1% | -2.0% | -0.5% | 11.0% |
| Valuation | |||||
| P/E | — | — | — | — | 11.65 |
| EV/EBITDA | 6.13 | 6.13 | 7.30 | 8.71 | 4.48 |
| P/B | 0.82 | 0.82 | 1.05 | 1.47 | 1.28 |
| Growth & Yield | |||||
| Revenue Growth | -1.3% | -1.3% | 1.1% | -12.3% | — |
| EPS Growth | — | — | -325.0% | -104.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → n/d
Residual
-10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.